Generic Exclusivity? Who Cares! Industry Offers Few Opinions On Potential Changes
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA officials still looking for input after transparency issue not widely addressed during GDUFA policy meeting.
You may also be interested in...
FDA’s Patent And Exclusivity Team Aims To Ensure Timely First Generics
Generic drugs office will proactively seek litigation and other information that could affect launch timing.
‘First Generic’ Definition Is Two-Sentence Tug Of War For FDA, Industry
FDA offers two-prong criteria to determine which ANDAs would get priority in review system; industry wants expanded classification that includes drug shortages.
ANDA Expedited Review Criteria MaPPed Out By FDA Generic Drug Office
CDER staff manual outlines seven categories of submissions that can qualify for expedited review, including some ANDAs with patent certifications and supplements that have the potential to create an “extraordinary hardship” for a sponsor if not addressed quickly.